Titel
Efficacy and Safety of a Targeted-Release Formulation of Budesonide in Patients with Primary IgA Nephropathy (NefIgArd):
2-year Results from a Randomised Phase 3 Trial
Referenz
Richard Lafayette et al.
Lancet. 2023 Sep 9;402(10405):859-870.
Fachrichtungen
Indikationen
IgA Nephropathie
Wirkstoffe
Budesonid
Schlagworte
IgA-Nephropathie